Drugs / DiaPep277
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01881958 | Jan 2015 → Jan 2016 | type 1 diabetes mellitus | Hadassah Medical Organization | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00058981 | Oct 2002 → Mar 2007 | autoimmune disease | DeveloGen Israel, Ltd. | Terminated | No outcome recorded |
| Phase 35 trials · 1 missed | ||||||
| Phase 3 | NCT01898286 | Oct 2013 → Sep 2014 | type 1 diabetes mellitus | Andromeda Biotech Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT01460251 | Jan 2012 → Dec 2014 | type 1 diabetes mellitus | Rabin Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT01103284 | Apr 2010 → Oct 2014 | type 1 diabetes mellitus | Andromeda Biotech Ltd. | Completed | Missed primary |
| Phase 3 | NCT00644501 | Sep 2008 → May 2013 | type 1 diabetes mellitus | Andromeda Biotech Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00615264 | Sep 2005 → Sep 2011 | type 1 diabetes mellitus | Andromeda Biotech Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DiaPep277 | “The optimal dose and dosing regimen for this study will be the same as applied in the phase 3 study (901) and its extension study protocol (910), namely 1.0 mg DiaPep277®...” NCT01460251 ↗ |
| Modality | Peptide | “DiaPep277 is a peptide” NCT01103284 ↗ |
| Route | Subcutaneous | “multiple subcutaneous doses of DiaPep277” NCT00058981 ↗ |